What is the appropriate management, dosing, and monitoring for a patient with rodenticide (rat‑kill) poisoning in the intensive care unit?

Management of Rodenticide (Rat-Kill) Poisoning in the ICU

Immediate Recognition and Stabilization

Long-acting anticoagulant rodenticides (LAARs) such as brodifacoum, bromadiolone, and difenacoum are the primary concern in rat-kill poisoning, causing severe coagulopathy through vitamin K epoxide reductase inhibition that can persist for weeks to months. 1

Initial Assessment and Monitoring

• Establish airway, breathing, and circulation using standard life-support measures immediately upon presentation. 2
• Contact your regional poison control center (1-800-222-1222 in the US) immediately for expert toxicology guidance; do not delay supportive care while awaiting consultation. 3, 2
• Measure baseline prothrombin time/INR at 36-48 hours post-exposure in all cases except young children with unintentional ingestion of <1 mg active ingredient. 4, 5
• Monitor continuously for bleeding manifestations: epistaxis, gingival bleeding, hematuria (most common), gastrointestinal bleeding, intracranial hemorrhage (most lethal), and spontaneous hemoperitoneum. 1, 4
• Obtain complete blood count to assess for anemia from occult blood loss. 4

Acute Hemorrhage Management

Active Bleeding Protocol

If active bleeding occurs with elevated INR, administer prothrombin complex concentrate (PCC) 50 units/kg IV as first-line therapy, combined with phytomenadione (vitamin K1) 10 mg IV (100 mcg/kg for children). 4

• Recombinant activated factor VII 1.2-4.8 mg IV is an alternative if PCC is unavailable. 4
• Fresh frozen plasma 15 mL/kg IV should only be used if neither PCC nor recombinant factor VII is available. 4
• Provide aggressive intravenous fluid resuscitation and hemodynamic support for hypovolemic shock from blood loss. 2, 4

Non-Bleeding Coagulopathy

• If INR ≥4.0 without active bleeding, administer phytomenadione 10 mg IV. 4
• If INR <4.0 without bleeding, no immediate treatment is required but continue monitoring. 4

Vitamin K1 Dosing and Duration

Initial/Acute Phase

For symptomatic patients or those with significant coagulopathy, initiate high-dose intravenous vitamin K1 at 50-100 mg or higher until bleeding is controlled and INR normalizes. 1

Maintenance Phase

After stabilization, transition to oral vitamin K1 at 100 mg daily as the most frequently required maintenance dose, though doses ranging from 10-120 mg/day may be needed. 1, 6

• Gradually taper the maintenance dose over time based on INR monitoring. 6
• Average treatment duration is 168 days (approximately 5-6 months), though some patients require therapy for weeks to months depending on the specific rodenticide. 1
• Monitor INR every 48-72 hours initially, then weekly during maintenance therapy. 5

Critical Monitoring Parameters

Laboratory Surveillance

INR normalization alone is insufficient to discontinue vitamin K1 therapy; serum LAAR concentrations should be measured to guide treatment discontinuation, as over half of patients have residual rodenticide levels >10 ng/mL despite normal INR. 7

• Measure serum LAAR concentrations at least twice during treatment to assess clearance. 7
• Continue vitamin K1 until serum LAAR concentration falls below 10 ng/mL to prevent rebound coagulopathy. 7
• Monitor for rebound coagulopathy after initial treatment due to the extremely high affinity of LAARs for vitamin K epoxide reductase. 1

Additional Monitoring

• Watch for paradoxical thrombosis and thrombotic complications, which have been observed in LAAR poisoning. 1
• Monitor hepatic function as LAARs accumulate in the liver. 4
• Consider phenobarbital administration to expedite LAAR metabolism in refractory cases. 1

Decontamination Considerations

Gastrointestinal decontamination with ipecac syrup or gastric lavage is not recommended for rodenticide poisoning. 5

• Activated charcoal may be considered only if presentation occurs within 1-2 hours of ingestion and the airway is protected, though evidence specific to rodenticides is limited. 3
• Do not delay transportation to the emergency department for activated charcoal administration. 5
• For dermal exposures, immediately wash skin thoroughly with soap and water while avoiding self-contamination. 2, 5

ICU-Specific Considerations

Patients requiring ICU admission typically present with life-threatening hemorrhage (especially intracranial), severe coagulopathy with INR beyond measurable limits, or hemodynamic instability from blood loss. 1, 4

• Maintain continuous cardiorespiratory monitoring and frequent neurological assessments to detect intracranial hemorrhage early. 1
• Ensure immediate availability of vitamin K1 (stocked in quantities sufficient for high-dose, prolonged therapy), PCC, and blood products. 8
• Prepare for potential need of mechanical ventilation if intracranial hemorrhage causes decreased consciousness. 4

Critical Pitfalls to Avoid

Do not discontinue vitamin K1 therapy based solely on INR normalization, as this leads to rebound coagulopathy and recurrent bleeding requiring rehospitalization. 7

• Do not assume a single dose or short course of vitamin K1 is sufficient; LAARs require prolonged therapy averaging 5-6 months. 1
• Do not delay vitamin K1 administration while awaiting laboratory confirmation of rodenticide type. 5
• Do not use warfarin dosing protocols for LAAR poisoning; these rodenticides require substantially higher and longer vitamin K1 therapy. 1
• Do not discharge patients from the ICU until bleeding is controlled, INR is stable on oral therapy, and outpatient monitoring is arranged. 5